Suppr超能文献

核苷酸序列改变的病毒量与口服脊髓灰质炎疫苗可接受性的猴体试验之间的相关性。

Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

作者信息

Chumakov K M, Powers L B, Noonan K E, Roninson I B, Levenbook I S

机构信息

Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892.

出版信息

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):199-203. doi: 10.1073/pnas.88.1.199.

Abstract

Production of live attenuated oral poliomyelitis vaccine (OPV) requires rigorous neurovirulence safety testing of each vaccine lot, currently carried out in monkeys. It has been reported that a change from 472-U to 472-C in the type 3 OPV RNA is associated with an increased histologic lesion score produced upon intraspinal inoculation of the mutant virus in monkeys. We have developed a method, based on polymerase chain reaction, for measuring the relative abundance of these mutant sequences directly in vaccine preparations and used this method to evaluate the proportion of 472-C in 40 different lots of type 3 OPV. Six vaccine lots that had failed the intraspinal monkey neurovirulence test contained a higher proportion of 472-C than all other lots that had passed this test. OPV type 3 virus containing 472-C was rapidly selected during serial passages in African green monkey kidney cells that are used for manufacturing of the vaccine. We have also found that the wild-type poliovirus type 3 strain Leon/37, from which the vaccine strain was originally derived, contained a mixture of 472-U and 472-C sequences. No other mutations in OPV type 3 RNA have been detected by similar assays at position 2034, also associated with attenuation, or at several other positions reported to be altered in some vaccine preparations. Our results suggest that molecular diagnostics may provide a supplement or a potential alternative to animal testing of live attenuated vaccines.

摘要

口服脊髓灰质炎减毒活疫苗(OPV)的生产需要对每一批疫苗进行严格的神经毒力安全性测试,目前该测试是在猴子身上进行的。据报道,3型OPV RNA中从472-U到472-C的变化与在猴子脊髓内接种突变病毒后产生的组织学损伤评分增加有关。我们开发了一种基于聚合酶链反应的方法,用于直接测量疫苗制剂中这些突变序列的相对丰度,并使用该方法评估40个不同批次的3型OPV中472-C的比例。六批未通过脊髓内猴子神经毒力测试的疫苗中472-C的比例高于所有通过该测试的其他批次。在用于生产疫苗的非洲绿猴肾细胞的连续传代过程中,含有472-C的3型OPV病毒被迅速选择出来。我们还发现,疫苗株最初源自的野生型3型脊髓灰质炎病毒Leon/37株含有472-U和472-C序列的混合物。在2034位(也与减毒有关)或一些疫苗制剂中报道发生改变的其他几个位置,通过类似检测未检测到3型OPV RNA的其他突变。我们的结果表明,分子诊断可能为减毒活疫苗的动物测试提供补充或潜在替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df47/50777/632237cac502/pnas01051-0216-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验